Award
NIH Reporter #5R01CA262462-05
Synthetic lethalities to cell cycle disruption in glioma
Recipient
Not specified
Award Amount
$673,491.00
Ceiling
$673,491.00
Awarded
June 11, 2026
Identifier
5R01CA262462-05
Research project funded by the National Cancer Institute to study the use of G2/M checkpoint inhibitors in glioma treatment, focusing on genetic vulnerabilities.
Description
This project aims to evaluate the potential of G2/M checkpoint inhibitors, especially CHK1/2 inhibitors, in treating gliomas, with a focus on genetic dependencies such as TP53 and CDKN2A/B loss. The research involves genomic characterization of glioma cell lines and aims to inform clinical trial strategies.